Novo Nordisk Stocks Drop 5% After 2026 Guidance Update Disappoints Investors
Novo Nordisk's US-traded shares dropped more than 5% on Tuesday after the Danish drugmaker released updated 2026 guidance that appeared to disappoint investors. The company now expects adjusted sales to be down 6% to flat at constant exchange rates, compared to a previous forecast of down 4% to 12%,
NVO1.03%
LucasBennett·08-04 17:36
